

The *c-myc*-Regulated Gene *mrl* Encodes Plasminogen Activator Inhibitor 1

GEORGE C. PRENDERGAST,*† LISA E. DIAMOND, DOUGLAS DAHL,
AND MICHAEL D. COLE

Department of Biology, Lewis Thomas Laboratory, Princeton University,
Princeton, New Jersey 08544-1014

Received 28 August 1989/Accepted 14 November 1989

The DNA sequence of the *c-myc*-regulated gene *mrl* (G. C. Prendergast and M. D. Cole, *Mol. Cell. Biol.* 9:124-134, 1989) reveals that it encodes plasminogen activator inhibitor 1 (PAI-1), a regulator of extracellular proteolysis. Comparison of the human and mouse PAI-1 promoters and cDNA 3' noncoding regions revealed several highly conserved sequence domains, potential targets for *c-myc* and other factors influencing PAI-1 expression. We discuss possible roles for PAI-1 in normal and neoplastic cell growth control.

Identification of the targets of oncogene activity is a central problem in the molecular biology of cancer. The *c-myc* oncogene encodes a nuclear protein which plays an important role in normal and abnormal cell proliferation (reviewed in references 7 and 14), although its targets and molecular function remain unknown. We recently identified a novel serum-regulated cellular gene, *mrl*, which is deregulated in *c-myc*-immortalized primary rodent fibroblasts and specifically induced by *c-myc* protein in 3T3 cell lines (30). The DNA sequence of murine *mrl* indicates that it is the rodent homolog of plasminogen activator inhibitor 1 (PAI-1), a regulator of extracellular proteases involved with various normal and pathological phenomena, including neoplasia (reviewed in references 8, 15, and 32).

A full-length murine *mrl* cDNA was obtained by standard methods (23) from a cDNA library constructed with RNA from BALB/c 3T3 cells treated with fetal calf serum plus cycloheximide (17), conditions which strongly induce *mrl* expression (G. C. Prendergast, Ph.D. thesis, Princeton University, Princeton, N.J., 1989). A restriction map and sequencing strategy are shown in Fig. 1A, and the complete cDNA sequence and predicted translation product are shown in Fig. 1B. The *mrl* cDNA is 3,014 base pairs (bp) long and contains a 1,206-bp open reading frame, encoding a 402-amino-acid polypeptide with a calculated molecular mass of 45,167 daltons. The predicted polypeptide sequence is ~78% identical (~82% with conservative substitutions) to that encoded by human PAI-1 cDNA (1, 26, 28) (Fig. 1C). A comparison of the 3' noncoding domains in the human and mouse PAI-1 cDNAs revealed extensive similarity in a 200-bp region about 400 bp upstream of the poly(A) tract (Fig. 2). Within this region is an unusual 100-bp stretch, starting at nucleotide 2445 in the mouse cDNA, which is >90% identical to the human PAI-1 message. The high conservation strongly suggests a role for this element in regulation of PAI-1 gene expression.

Transcriptional induction of PAI-1 in 3T3 cells by platelet-derived growth factor (30) prompted us to locate control

elements in the PAI-1 promoter. As a first step toward this goal, we searched the mouse PAI-1 promoter for DNA sequence conserved in the human gene (3). Genomic clones were isolated from an EMBL 3 library (Clontech Laboratories), and a region of ~1.4 kilobases encompassing the murine promoter and noncoding exon 1 was sequenced and compared with the human gene (Fig. 3). Three broad segments of conserved DNA sequence were observed. The first was across the exon 1 splice donor junction, a 45-bp block which is 87% identical to human PAI-1. The second was an ~210-bp segment within the proximal region of the promoter. At 29 bp upstream of the 5' PAI-1 mRNA cap site was a TATAA transcription start consensus sequence, which was embedded within a 65-bp region with 96% identity between human and mouse genes (proximal box). Two cap sites are utilized by the PAI-1 promoter in mouse 3T3 fibroblasts, both adenosine residues; each site is used with about equal efficiency (Prendergast, Ph.D. thesis; data not shown). Approximately 400 bp distal to the TATAA consensus is a 300-bp segment which is 76% identical between the genes; within this region are several blocks of sequence identity (distal box). Relative to the human PAI-1 promoter, the mouse promoter has a gap of ~100 bp between the proximal and distal boxes of homology.

As the first cellular gene known to be regulated by *c-myc* protein in stable cell assays (30), the PAI-1 gene may be potentially useful as a substrate with which to uncover the molecular function of the *c-myc* oncoprotein. PAI-1 is somewhat unusual (like *c-myc*) in that it is expressed during both the G₀ to G₁ cell cycle transition and in cycling cells (30), which do not enter the G₀ phase (29). More commonly, serum- and platelet-derived growth factor-regulated genes are well expressed during G₀ to G₁ but not in cycling cells (31; unpublished observations). We speculate that PAI-1 expression is required generally during fibroblast proliferation. Platelet-derived growth factor is added to a growing list of factors which regulate the PAI-1 gene in several systems, including transforming growth factor-beta (16, 21), glucocorticoids (12), interleukin-1 (2), lipopolysaccharide (33), tumor necrosis factor alpha (33), thrombin (10) and other factors (see reference 33 for an extensive listing). PAI-1 cDNA has also been isolated by Bravo and his associates (4) in a screen for serum-induced mRNAs in NIH 3T3 cells.

* Corresponding author.

† Present address: Department of Biochemistry, New York University Medical Center, 550 First Avenue, New York, NY 10016.




FIG. 1. *mrl* cDNA encodes murine PAI-1. (A) Restriction map and sequencing strategy of a full-length murine *mrl* cDNA. The dark bar represents the 1,206-bp polypeptide open reading frame; the open box indicates a 3' noncoding region highly similar to the human PAI-1 cDNA (see text). Enzyme abbreviations are Bgl, *BglII*; D, *DraI*; H, *HindIII*; Hc2, *HindII*; Nco, *NcoI*; S, *SacI*; Xho, *XhoI*. (B) Complete DNA sequence of the *mrl* cDNA. The single-letter amino acid code is used for the inferred translation product of the 1,206-bp polypeptide open reading frame. (C) Amino acid similarity between human PAI-1 and the inferred polypeptide encoded by the *mrl* cDNA. Dashes indicate identity; colons indicate conservative substitutions.




FIG. 3. Sequence similarity between 5' noncoding regions of the murine and human PAI-1 genes. The human sequence and mRNA cap designation are from Bosma et al. (3). The asterisks designate exon 1, and the carats indicate the mRNA caps sites; the TATAA consensus is underlined.

to its well-characterized role in protease inhibition. Clearly, further studies are necessary to assess the contributions of PAI-1 to cell growth decisions.

We thank B. Christy and D. Nathans for the λ gt10 cDNA library,

James Lin for genomic cloning, and Michelle Aman and Mary Ellen Steele for technical assistance.

This work was supported by a Public Health Service grant to M.D.C. from the National Institutes of Health. G.C.P. was supported by a Public Health Service genetics training grant, and

L.E.D. was supported by a postdoctoral fellowship from the American Cancer Society. M.D.C. is a Pew Scholar in the Biomedical Sciences.

LITERATURE CITED

- Andreasen, P. A., A. Riccio, K. G. Welinder, R. Douglas, R. Sartorio, L. S. Nielsen, C. Oppengeimer, F. Blasi, and K. Dano. 1986. Plasminogen activator inhibitor type-1: reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing. *FEBS Lett.* **209**:213–218.
- Bevilacqua, M. P., R. R. Schleef, M. A. Gimbrone, and D. J. Loskutoff. 1986. Regulation of the fibrinolytic system of cultured human vascular endothelium by interleukin 1. *J. Clin. Invest.* **78**:587–591.
- Bosma, P. J., E. S. van den Berg, T. Kooistra, D. R. Siemieniak, and J. L. Lightom. 1988. Human plasminogen activator inhibitor-1 gene: promoter and structural gene nucleotide sequences. *J. Biol. Chem.* **263**:9129–9141.
- Bravo, R., M. Zerial, L. Toschi, M. Schurmann, R. Muller, S. I. Sirai, M. Yaniv, J. M. Almendral, and R.-P. Ryseck. 1988. Identification of growth factor-inducible genes in mouse fibroblasts. *Cold Spring Harbor Symp. Quant. Biol.* **53**:901–905.
- Carroll, R., and J. Travis. 1985. Alpha-1-antitrypsin and the serpins: variation and countervariation. *Trends Biochem. Sci.* **10**:20–24.
- Cohen, R. L., J. Niclas, W. M. F. Lee, T.-C. Wun, C. W. Crowley, A. D. Levinson, J. E. Sadler, and M. A. Shuman. 1989. Effect of transformation on expression of plasminogen activator inhibitors 1 and 2: evidence for independent regulation. *J. Biol. Chem.* **264**:8375–8383.
- Cole, M. D. 1986. The *myc* oncogene: its role in transformation and differentiation. *Annu. Rev. Genet.* **13**:361–384.
- Dano, K., P. A. Andreasen, J. Grondahl-Hansen, B. Kristensen, L. S. Nielsen, and L. Skriver. 1985. Plasminogen activators, tissue degradation and cancer. *Adv. Cancer Res.* **44**:146–239.
- Erickson, L. A., C. M. Hekman, and D. J. Loskutoff. 1985. The primary plasminogen-activator inhibitors in endothelial cells, platelets, serum, and plasma are immunologically related. *Proc. Natl. Acad. Sci. USA* **82**:8710–8714.
- Gelehrter, T. D., and R. Szyner-Laszuk. 1986. Thrombin induction of plasminogen activator inhibitor in cultured endothelial cells. *J. Clin. Invest.* **77**:165–169.
- Gloor, S., K. Odink, J. Guenther, H. Nick, and D. Monard. 1986. A glia-derived neurite promoting factor with protease inhibition activity belongs to the protease nexins. *Cell* **47**:687–693.
- Heaton, J. H., and T. D. Gelehrter. 1989. Glucocorticoid induction of plasminogen activator and plasminogen activator-inhibitor messenger RNA in rat hepatoma cells. *Mol. Endocrinol.* **3**:349–355.
- Kelekar, A., and M. D. Cole. 1987. Immortalization by *myc*, *H-ras*, and *E1a* oncogenes induces differential gene expression and growth factor responses. *Mol. Cell. Biol.* **7**:3899–3907.
- Kelly, K., and U. Siebenlist. 1986. The regulation and expression of *c-myc* in normal and malignant cells. *Annu. Rev. Immunol.* **4**:317–338.
- Laiho, M., and J. Keski-Oja. 1989. Growth factors in regulation of pericellular proteolysis: a review. *Cancer Res.* **49**:2533–2553.
- Laiho, M., O. Saksela, and J. Keski-Oja. 1987. Transforming growth factor-beta induction of type-1 plasminogen activator inhibitor: pericellular deposition and sensitivity to exogenous urokinase. *J. Biol. Chem.* **262**:17467–17474.
- Lau, L., and D. Nathans. 1987. Expression of a set of growth-related immediate early genes in BALB/c 3T3 cells: co-ordinate regulation with *c-fos* or *c-myc*. *Proc. Natl. Acad. Sci. USA* **84**:1182–1186.
- Levin, E. G., and L. Santell. 1987. Association of a plasminogen activator inhibitor (PAI-1) with the growth substratum and membrane of human endothelial cells. *J. Cell Biol.* **105**:2543–2549.
- Loskutoff, D. J., K. Roegner, L. A. Erickson, R. R. Schleef, A. Huttenlocher, P. L. Coleman, and T. D. Gelehrter. 1986. The dexamethasone-induced inhibitor of plasminogen activator in hepatoma cells is antigenically-related to a inhibitor produced by bovine aortic endothelial cells. *Thromb. Haemostasis* **55**:8–11.
- Loskutoff, D. J., J. A. van Mourik, L. A. Erickson, and D. Lawrence. 1983. Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. *Proc. Natl. Acad. Sci. USA* **80**:2956–2960.
- Lund, L. R., A. Riccio, P. A. Andreasen, L. S. Nielsen, P. Kristensen, M. Laiho, O. Saksela, F. Blasi, and K. Dano. 1987. Transforming growth factor-beta is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts. *EMBO J.* **6**:1281–1286.
- Lyons, R. M., J. Keski-Oja, and H. Moses. 1988. Proteolytic activation of latent transforming growth factor-beta from fibroblast conditioned medium. *J. Cell Biol.* **106**:1659–1665.
- Maniatis, T., E. F. Fritsch, and J. Sambrook. 1982. *Molecular cloning: a laboratory manual.* Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
- McKeehan, W. L., Y. Sakagami, H. Hoshi, and K. A. McKeehan. 1986. Two apparent human endothelial cell growth factors from human hepatoma cells are tumor-associated proteinase inhibitors. *J. Biol. Chem.* **261**:5378–5383.
- Mignatti, P., E. Robbins, and D. B. Rifkin. 1986. Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. *Cell* **47**:487–498.
- Ny, T., M. Sawdey, D. Lawrence, J. L. Millan, and D. J. Loskutoff. 1986. Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor. *Proc. Natl. Acad. Sci. USA* **83**:6776–6780.
- Ossowski, L. 1988. Plasminogen activator dependent pathways in the dissemination of human tumor cells in the chick embryo. *Cell* **52**:321–328.
- Pannekoek, H., H. Veerman, H. Lambers, P. Diergaarde, C. L. Verweij, A.-J. van Zonneveld, and J. A. van Mourik. 1986. Endothelial plasminogen activator inhibitor (PAI): a new member of the serpin gene family. *EMBO J.* **5**:2539–2544.
- Pardee, A. B., R. Dubrow, J. L. Hamlin, and R. F. Kletzien. 1978. Animal cell cycle. *Annu. Rev. Biochem.* **47**:715–750.
- Prendergast, G. C., and M. D. Cole. 1989. Posttranscriptional regulation of cellular gene expression by the *c-myc* oncogene. *Mol. Cell. Biol.* **9**:124–134.
- Rollins, B. J., E. D. Morrison, and C. D. Stiles. 1987. A cell cycle constraint on the regulation of gene expression by platelet-derived growth factor. *Science* **238**:1269–1271.
- Saksela, O., and D. B. Rifkin. 1988. Cell-associated plasminogen activation: regulation and physiological functions. *Annu. Rev. Cell Biol.* **4**:93–126.
- Sawdey, M., T. J. Podor, and D. J. Loskutoff. 1989. Regulation of type-1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. *J. Biol. Chem.* **264**:10396–10401.
- Sprengers, E. D., and C. Kluft. 1987. Plasminogen activator inhibitors. *Blood* **69**:381–387.
- van Mourik, J. A., D. A. Lawrence, and D. J. Loskutoff. 1984. Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. *J. Biol. Chem.* **259**:14914–14921.
- Wun, T.-C., M. O. Palmier, N. R. Siegel, and C. E. Smith. 1989. Affinity purification of active plasminogen activator inhibitor-1 (PAI-1) using immobilized anhydrourokinase: demonstration of binding, stabilization, and activation of PAI-1 by vitronectin. *J. Biol. Chem.* **264**:7862–7868.